Bosentan Dr. Reddy’s 62.5mg Film-Coated Tablets यूनाइटेड किंगडम - अंग्रेज़ी - myHealthbox

bosentan dr. reddy’s 62.5mg film-coated tablets

dr. reddy’s laboratories (uk) ltd. - bosentan - film-coated tablet - 62.5mg - other antihypertensives - treatment of pulmonary arterial hypertension (pah) to improve exercise capacity and symptoms in patients with who functional class iii. efficacy has been shown in: • primary (idiopathic and heritable) pulmonary arterial hypertension • pulmonary arterial hypertension secondary to scleroderma without significant interstitial pulmonary disease • pulmonary arterial hypertension associated with congenital systemic-topulmonary shunts and eisenmenger’s physiology

Bosentan Dr. Reddy’s 125mg Film-Coated Tablets यूनाइटेड किंगडम - अंग्रेज़ी - myHealthbox

bosentan dr. reddy’s 125mg film-coated tablets

dr. reddy’s laboratories (uk) ltd. - bosentan - film-coated tablet - 125mg - other antihypertensives - treatment of pulmonary arterial hypertension (pah) to improve exercise capacity and symptoms in patients with who functional class iii. efficacy has been shown in: • primary (idiopathic and heritable) pulmonary arterial hypertension • pulmonary arterial hypertension secondary to scleroderma without significant interstitial pulmonary disease • pulmonary arterial hypertension associated with congenital systemic-topulmonary shunts and eisenmenger’s physiology

Budesonide/Formoterol Teva Pharma B.V. यूरोपीय संघ - अंग्रेज़ी - EMA (European Medicines Agency)

budesonide/formoterol teva pharma b.v.

teva pharma b.v. - budesonide, formoterol - asthma - drugs for obstructive airway diseases, - budesonide/formoterol teva pharma b.v. is indicated in adults 18 years of age and older only.asthmabudesonide/formoterol teva pharma b.v. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate: orin patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists.in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.